Aspects on the Physiological and Biochemical Foundations of Neurocritical Care by Nordström, Carl-Henrik et al.
Syddansk Universitet
Aspects on the Physiological and Biochemical Foundations of Neurocritical Care
Nordström, Carl-Henrik; Koskinen, Lars-Owe ; Olivecrona, Magnus
Published in:
Frontiers in Neurology
DOI:
10.3389/fneur.2017.00274
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Nordström, C-H., Koskinen, L-O., & Olivecrona, M. (2017). Aspects on the Physiological and Biochemical
Foundations of Neurocritical Care. Frontiers in Neurology, 8, [274]. DOI: 10.3389/fneur.2017.00274
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. aug.. 2017
June 2017 | Volume 8 | Article 2741
Review
published: 19 June 2017
doi: 10.3389/fneur.2017.00274
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Niklas Marklund, 
Lund University, Sweden
Reviewed by: 
Parmenion P. Tsitsopoulos, 
Aristotle University of 
Thessaloniki, Greece  
Baback Arshi, 
University of Illinois at Chicago, 
United States  
Elham Rostami, 
Uppsala University 
Hospital, Sweden
*Correspondence:
Carl-Henrik Nordström 
carl-henrik.nordstrom@med.lu.se
Specialty section: 
This article was submitted 
to Neurocritical and 
Neurohospitalist Care, 
a section of the journal 
Frontiers in Neurology
Received: 28 March 2017
Accepted: 29 May 2017
Published: 19 June 2017
Citation: 
Nordström C-H, Koskinen L-O and 
Olivecrona M (2017) Aspects on the 
Physiological and Biochemical 
Foundations of Neurocritical Care. 
Front. Neurol. 8:274. 
doi: 10.3389/fneur.2017.00274
Aspects on the Physiological and 
Biochemical Foundations of 
Neurocritical Care
Carl-Henrik Nordström1*, Lars-Owe Koskinen 2 and Magnus Olivecrona3,4
1 Department of Neurosurgery, Odense University Hospital, Odense, Denmark, 2 Department of Clinical Neuroscience, 
Division of Neurosurgery, Umeå University, Umeå, Sweden, 3 Faculty of Health and Medicine, Department of Anesthesia and 
Intensive Care, Section for Neurosurgery Örebro University Hospital, Örebro University, Örebro, Sweden, 4 Department for 
Medical Sciences, Örebro University, Örebro, Sweden
Neurocritical care (NCC) is a branch of intensive care medicine characterized by specific 
physiological and biochemical monitoring techniques necessary for identifying cerebral 
adverse events and for evaluating specific therapies. Information is primarily obtained 
from physiological variables related to intracranial pressure (ICP) and cerebral blood 
flow (CBF) and from physiological and biochemical variables related to cerebral energy 
metabolism. Non-surgical therapies developed for treating increased ICP are based 
on knowledge regarding transport of water across the intact and injured blood–brain 
barrier (BBB) and the regulation of CBF. Brain volume is strictly controlled as the BBB 
permeability to crystalloids is very low restricting net transport of water across the 
capillary wall. Cerebral pressure autoregulation prevents changes in intracranial blood 
volume and intracapillary hydrostatic pressure at variations in arterial blood pressure. 
Information regarding cerebral oxidative metabolism is obtained from measurements of 
brain tissue oxygen tension (PbtO2) and biochemical data obtained from intracerebral 
microdialysis. As interstitial lactate/pyruvate (LP) ratio instantaneously reflects shifts 
in intracellular cytoplasmatic redox state, it is an important indicator of compromised 
cerebral oxidative metabolism. The combined information obtained from PbtO2, LP ratio, 
and the pattern of biochemical variables reveals whether impaired oxidative metabolism 
is due to insufficient perfusion (ischemia) or mitochondrial dysfunction. Intracerebral 
microdialysis and PbtO2 give information from a very small volume of tissue. Accordingly, 
clinical interpretation of the data must be based on information of the probe location 
in relation to focal brain damage. Attempts to evaluate global cerebral energy state 
from microdialysis of intraventricular fluid and from the LP ratio of the draining venous 
blood have recently been presented. To be of clinical relevance, the information from 
all monitoring techniques should be presented bedside online. Accordingly, in the 
future, the chemical variables obtained from microdialysis will probably be analyzed by 
biochemical sensors.
Keywords: neurocritical care, intracranial pressure, cerebral blood flow, cerebral energy metabolism, microdialysis
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iNTRODUCTiON
Critical—or intensive—care medicine is defined as a branch 
of medicine concerned with the diagnosis and treatment of 
life-threatening conditions requiring invasive monitoring and 
advanced pharmacological or technical organ support. After 
a serious polio epidemic with many deaths due to insufficient 
respiration, the first critical care unit in the world opened at 
Kommunehospitalet in Copenhagen in December 1953 (1). 
Since then, critical care medicine has gradually developed and 
holds today a central position within medicine (2). Neurocritical 
care (NCC) emerged as a separate branch in the 1980s. It was 
introduced to improve outcome in serious diseases of the nerv-
ous system, e.g., stroke, cerebral trauma, brain swelling, seizures, 
and central nervous infections. In addition to the components 
included in general critical care, NCC is especially focused on 
problems related to intracranial pressure (ICP), cerebral blood 
flow (CBF), and cerebral energy metabolism (3). During NCC, 
information regarding these physiological and biochemical 
variables may be obtained, displayed bedside and included in the 
clinical decision making. In this review, we present some of the 
most widely used monitoring techniques and discuss how they 
may be used and interpreted to evaluate and optimize therapy.
iCP MONiTORiNG AND vOLUMe 
ReGULATiON OF THe BRAiN
iCP Monitoring—Principles and 
Techniques
In the 1950s, Nils Lundberg developed the first clinical technique 
for continuous monitoring of ICP (4). He used a simple technique 
where a catheter was inserted into the cerebrospinal fluid (CSF) 
of the lateral ventricle through a frontal burr hole. The ventricular 
cannula was then via a strain gage pressure transducer connected 
to a potentiometer recorder, and the ICP was displayed bedside 
online. The technique has remained the “gold standard” for ICP 
monitoring (5) due to several advantages: as calibration is pos-
sible, the data obtained are accordingly always correct, and CSF 
may be drained to decrease ICP. The technique is not without risk 
but serious complications like hemorrhages and intraventricular 
infection can be kept at a low and acceptable level (5). However, 
it can be technically difficult to insert the ventricular catheter in 
patients with compressed or dislocated ventricles.
Techniques utilizing intra-parenchymal ICP recording 
circumvent some of these problems. Several technical solutions 
are available utilizing fiberoptic tips or micro strain gages. The 
fiberoptic sensor utilizes the path length change induced by 
pressure applied to a diaphragm. The miniaturized strain gage 
sensors have a foil responding with a change in resistance as stress 
is supplied and the strain gage element is connected to a half or 
complete Wheatstone bridge circuit. This technique is common 
for many pressure transducers used in medicine. A principle 
difference from the intraventricular technique is the inability to 
recalibrate the intra parenchymal transducers (5–8). In addition, 
these devises may measure a compartmentalized local pressure 
(9). Some of the transducers show a low zero drift and have 
very low complication rates (10, 11). A non-invasive technique 
of monitoring ICP to replace the invasive measures mentioned 
would seem attractive. To be of value during NCC, it must pro-
vide a continuous and accurate bedside measure of ICP. Presently, 
there is no such technique available (5, 12).
volume Regulation of the Brain
Since the intracranial space constitutes an almost completely 
closed compartment, the dynamics of the ICP is determined by 
the physiological regulation of the contributing volumes: the CSF 
volume, the cerebral blood volume (CBV), and, most important, 
the volume of the brain tissue itself. In this section, we focus on 
the physiological regulation of brain tissue volume and in the 
subsequent section on the regulation of CBF we discus aspects 
on the regulation of CBV.
Like in other organs, the volume regulation of the brain is 
mainly determined by controlling the fluid exchange across the 
capillaries. Due to the blood brain barrier (BBB), the brain differs 
from other organs regarding these mechanisms. In addition to its 
other vital physiological functions, the BBB is the most impor-
tant regulator of cerebral volume (13). The flux of water across a 
microvascular bed (Jv) is described by Eq. 1:
 J L A Pv p s s= × × ∆ − ×∆∑   [ ]σ ∏  (1)
Lp represents the specific permeability for water (hydraulic 
conductivity), A is the surface area available for fluid exchange, 
ΔP is the transcapillary hydrostatic pressure difference, ΔΠs the 
transcapillary osmotic pressure difference, and σs the reflection 
coefficient of each solute (s) of the system. The product Lp × A is 
denoted hydraulic conductance and reflects the total capacity for 
fluid exchange. Transcapillary water exchange is thus determined 
by the following factors: the hydraulic conductance of the capil-
lary wall (Lp × A), the differences in hydrostatic pressure (ΔP) and 
osmotic pressure gradient (ΔΠs) across the capillary wall, and the 
endothelial component determining which solutes are reflected 
and will contribute to the osmotic pressure gradient (σs).
The effective osmotic pressure across a membrane that is 
partly permeable to the solutes is less than the theoretical osmotic 
pressure. The reflection coefficient (σs) accounts for this differ-
ence (13). The value of σ depends on the relative permeabilities 
of the membrane to water and to solute: if the membrane is 
impermeable to the solute but not to water σ equals 1, and if the 
permeability of the solute is identical to the diffusion coefficient 
in water σ equals 0. Table 1 gives the reflections coefficients of 
some clinically important solutes for the BBB (14). Sodium and 
chloride, which are the two major solutes of biological fluids, have 
BBB reflection coefficients of 1.0. Water passing the BBB in any 
direction will thus be very dilute regarding crystalloids.
The magnitude of the hydraulic conductance (Lp × A) describes 
the rate by which water is transferred across the BBB whenever 
there is driving force (ΔP − ∑σ × ΔΠ). The only way of induc-
ing transcapillary filtration or absorption is accordingly to affect 
the balance between the hydrostatic and osmotic forces across 
the capillary membrane. Under physiological conditions, varia-
tions in cerebral perfusion pressure (CPP; CPP = MAP − ICP) 
and intracerebral capillary hydrostatic pressure are of limited 
TABLe 1 | The reflection coefficients (see text) of various substances for the 
blood–brain barrier (BBB).
Solute Reflection coefficient 
BBB
Urea 0.44–0.59
Glycerol 0.48
Mannitol 0.90
Sucrose 0.91–1.00
NaCl 1.00
Albumin 1.00
Data from Fenstermacher (13) and Staverman (14).
FiGURe 1 | Schematic illustration of water exchange across cerebral capillaries in three hypothetical situations: (A) the normal brain with intact blood–brain barrier 
(BBB); (B) the injured brain with a BBB permeable for crystalloids but not colloids; (C) the injured brain with a ruptured BBB permeable for crystalloids as well as 
colloids. Gray area represents crystalloids in the capillary; black circles represent large (colloidal) molecules; filled gray circles represent blood cells.
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importance for brain volume. First, intracapillary pressure is 
physiologically tightly autoregulated (see Regulation of CBF) and 
variations in systemic blood pressure are generally not transmitted 
to cerebral capillaries. Second, as described above, transcapillary 
fluid exchange is effectively counteracted by the low perme-
ability to crystalloids combined with their high osmotic pressure 
(≈5,700 mmHg) on both sides of the BBB (13). This contrasts to 
most other capillary regions where the osmotic pressure force is 
mainly derived from the difference between plasma and intersti-
tial colloid osmotic pressure, which approximately balance the 
transcapillary hydrostatic pressure (≈20 mmHg). Water passing 
the BBB in any direction will accordingly not be accompanied by 
crystalloids. If, due to a difference in hydrostatic pressure, water 
passes the BBB an opposing osmotic gradient will immediately be 
created. Thus, the brain volume is under physiological conditions 
relatively independent of variations in intracapillary hydrostatic 
and colloid osmotic pressure (Figure 1). This volume control is, 
however, not unlimited. Although the reflection coefficient is 
about 1 for several solutes (Table 1) the half times for exchange 
of solutes like sodium and chloride indicate that a slow influx 
of solutes will in time dissipate the volume-controlling osmotic 
gradient. Accordingly, the long-term control of brain volume also 
depends on other mechanisms.
The lymphatic system plays an important role for volume 
regulation in most organs by draining interstitial fluid. Drainage 
of cerebral extracellular fluid has also been shown to occur via 
cranial nerves and spinal nerve roots (15, 16). This lymphatic 
drain has been suggested to be of importance for the immuno-
reactivity of the brain (16, 17) but is probably unimportant for 
cerebral volume regulation. The brain uses the CSF system as an 
alternative. The importance of this pathway for volume regulation 
is, however, disputed. Some studies have indicated that due to 
the tortuous nature of the extracellular space bulk fluid flow is 
negligible during physiological conditions and there are conflict-
ing data regarding bulk flow between white matter and CSF in 
normal animals (18–22). In experimental brain edema, transport 
of extracellular fluid into the ventricular space has been described 
(23), but this mechanism for removing edema fluid does not solve 
the primary problem—the formation of edema fluid by leaky 
cerebral microvessels.
Summary: iCP Monitoring and volume 
Regulation of the Brain
Continuous, accurate monitoring of ICP and mean arterial 
pressure (MAP) is of fundamental importance for NCC. All 
non-surgical treatments of increased ICP are based on knowledge 
regarding the physiological volume regulation of the brain.
FiGURe 3 | Schematic illustration of the relation between arterial tension of 
CO2 (PaCO2) and cerebral blood flow (CBF). The interrupted arrows indicate 
the decrease in CBF during a decrease in PaCO2 due to hyperventilation.
FiGURe 2 | Schematic illustration of the brain and its surroundings being 
enclosed in a rigid shell (CSF, cerebrospinal fluid). The vessels responsible  
for precapillary vascular resistance (1) as well as the intracerebral venous 
compartment (2) are indicated in the figure.
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CBF AND CBF ReGULATiON
Principles and Techniques
A technique for quantitative, repeated measurements of CBF, 
which could be used under clinical conditions, was presented 
in the early 1960s. A radioactive tracer (85Kr) was administered 
to the brain via the arterial blood supply, and its clearance was 
registered with an extracranial detector (24, 25). Later develop-
ments of the original technique have had a major impact on our 
knowledge regarding CBF and the regulation of CBF during 
physiological and patho-physiological conditions.
Mobile CT units have been developed to be used in NCC, 
and Xe-enhanced CT scanning gives useful information regard-
ing regional CBF (26). However, as the CT scanner is not CE 
labeled, it is presently not available in Europe. Positron emission 
tomography and magnetic resonance tomography techniques are 
giving good information of CBF but do not allow for continuous 
measurements and can hardly be used in NCC. Accordingly, it 
may be concluded that there is presently no technique available 
for continuous, quantitative monitoring of global or regional CBF 
during NCC.
Many attempts have been made to measure CBF using ultra-
sound Doppler methods. However, the method gives blood flow 
velocities which should not be interpreted as blood flow. Laser 
Doppler technique, mainly used in research, is available but gives 
relative values and the measuring volume is small. The Bowman 
perfusion monitor (Hemedex®, Hemedex Inc., Cambridge, MA, 
USA) is a rather new device measuring focal CBF by a thermo-
dilution technique and gives blood flow in ml/min/100 g (27, 28). 
The device has the drawback of being sensitive for temper-
ature changes. The device can be used for brain temperature 
measurements.
Regulation of CBF
The tight regulation of CBF secures a sufficient, continuous sup-
ply of glucose and oxygen to support the high metabolic demands 
of the brain (29). The control of CBF also affects two physiological 
parameters of importance for ICP: the intracapillary hydrostatic 
pressure and the intracerebral blood volume. The dynamics of 
ICP are closely related to three conventionally described physi-
ological regulators of CBF: regulation by carbon dioxide (CO2 
regulation), metabolic regulation, and pressure autoregulation. 
All regulators of CBF primarily act by affecting the resistance at 
the precapillary vessel level (Figure 2).
CO2 Regulation
Controlled normal ventilation (PaCO2 4.7–6.0 kPa) is currently 
the goal for severe traumatic brain injury (TBI) patients in the 
absence of cerebral herniation (30). Hyperventilation is fre-
quently used during intensive care to achieve a rapid reduction 
of CBF leading to a reduction of CBV and ICP. This immediate 
effect (CO2 regulation) is caused by a pH-dependent constric-
tion of precapillary resistance vessels (Figures 2 and 3) (29, 31). 
However, because the perivascular increase in pH induced by 
hyperventilation is compensated metabolically within a few 
hours, the reduction of CBF and CBV is transient despite pre-
served hypocapnia. Accordingly, the decrease in ICP does not 
last (32). Pronounced hyperventilation may also carry a risk of 
inducing focal ischemia (33, 34), but the clinical importance of 
the potential risk remains controversial (35, 36). A pro/con debate 
on the whether PaCO2 should be tightly controlled in all patients 
with acute brain injuries recently addressed this controversial 
issue (37).
Finally, as discussed later, as a result of impaired cerebrovas-
cular CO2 reactivity, hyperventilation often does not reduce CBV 
(and ICP) in patients with very severe brain injuries (38–40).
Metabolic Regulation
Figure 4 schematically illustrates the relation between cerebral 
metabolic rate and CBF. Data are based on experimental stud-
ies of epileptic seizures (41, 42), immobilization stress (43, 44), 
and administration of amphetamine (45) and barbiturate (46). 
Cerebral metabolic rate and CBF are generally reduced during 
coma (29). Hypoglycemic coma is an exception. In this condition, 
CBF is markedly increased (47).
A reduction of cerebral energy metabolism is usually accom-
panied by a lasting vasoconstriction and reduction of CBF and 
CBV (Figure 4). The effect may be induced pharmacologically—
e.g., by administration of barbiturates (39)—on condition that 
FiGURe 5 | Schematic illustration of cerebral pressure autoregulation of 
blood flow: the relation between mean arterial blood pressure (MAP)/cerebral 
perfusion pressure (CPP) and cerebral blood flow (CBF)/intracapillary 
hydrostatic pressure. Line A indicates intact autoregulation; line C indicates 
absence of autoregulation; line B indicates the description of absence of 
autoregulation often given in neurosurgical literature. The point A/B illustrates 
that in neurosurgical literature intact autoregulation is often interpreted as a 
mechanism preventing a decrease in CBF at a decrease in MAP/CPP.
FiGURe 4 | Illustration of the relation between cerebral metabolic rate and 
cerebral blood flow (CBF). The figure gives a schematic summary of data 
obtained from experimental studies during induced epileptic seizures (41, 42) 
and immobilization stress (43, 44), and after administration of amphetamine 
(45) and phenobarbitone (46).
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cerebrovascular CO2 reactivity is preserved (48, 49). The clinical 
usefulness of barbiturate coma is further reduced by the fact 
that prolonged high-dose barbiturate therapy is associated with 
pulmonary, cardiovascular, and other serious complications (50). 
Several other drugs that decrease cerebral energy metabolism 
also decrease CBF and CBV. Propofol has been used extensively 
for sedating patients when rapid awakening is desirable (51). 
However, propofol is associated with several complications and 
long-term propofol infusion has been related to severe adverse 
effects and mortality (52–55).
Pressure Autoregulation
Pressure autoregulation of CBF was first described by the 
Danish neurologist Mogens Fog (56, 57). As a result of the pres-
sure autoregulation, CBF remains relatively constant, despite 
variations in perfusion pressure within certain limits (Figure 5) 
(56–58). In neurosurgical literature, the physiological importance 
of this mechanism is often interpreted as protecting the brain 
from a decline in CBF (Figure 5, line B) if CPP decreases below a 
certain limit (AB). In physiological literature, however, autoregu-
lation is described as a mechanism that primarily serves to keep 
intracapillary hydrostatic pressure constant. In this literature, 
if autoregulation is impaired, then blood flow is described to 
increase passively according to line C in Figure 5 (59, 60).
The vessels responsible for pressure autoregulation have been 
studied in experimental animals equipped with cranial windows 
for the direct observation of the cortical microcirculation (61). 
The large surface cerebral vessels (200–400 µm in diameter) were 
the most reactive to changes in blood pressure and were respon-
sible for autoregulation between pressures of 120 and 160 mmHg. 
They also played the predominant role in minimizing changes in 
flow at pressures as low as 70–80 mmHg. The small surface and 
intracerebral arterioles did not change caliber when arterial pres-
sure varied between 90 and 160 mmHg but, above 160 mmHg, 
they underwent forced dilation and contributed to the increase 
in blood flow observed.
Myogenic, metabolic, and neurogenic theories have been 
proposed to explain cerebral pressure autoregulation (62, 63). 
Additionally, endothelium-related factors have been suggested, 
and some studies have indicated a possible role for nitric oxide as 
a vasodilator during reduced CPP (64, 65). However, other stud-
ies have reported that nitric oxide may be a mediator of chem-
oregulation, but not autoregulation (66). Currently, it may be 
summarized that the mechanisms responsible for autoregulation 
are not completely understood and that the primary physiological 
function is to keep capillary hydrostatic pressure within narrow 
limits, despite variations in CPP. Additionally, vasodilatation may 
protect the brain from a fall in CBF during a moderate reduction 
in CPP.
For a quantitative evaluation of cerebrovascular resistance, it is 
necessary to measure blood flow and perfusion pressure. As there 
are no suitable techniques available for continuous monitoring 
of CBF during NCC and as autoregulation has been regarded 
as a clinically important phenomenon, various techniques for 
circumventing this problem have been presented (67). Of these, 
the so-called pressure reactivity index (PRx) has attracted most 
attention (68, 69).
Pressure reactivity index is based on continuous monitoring of 
the association between slow spontaneous waves in ICP and arte-
rial blood pressure (ABP). It is calculated as a moving correlation 
coefficient between consecutive samples of values for ICP and 
ABP averaged for a defined period of time. For example, PRx may 
be calculated as the correlation coefficient between 30 consecu-
tive average values over 10 s of MABP and ICP (altogether 5 min). 
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This 5-min window may be moved forward in increments of 12 s, 
generating five PRx values each minute and 1-min average for 
PRx may be calculated and presented (68). In studies, PRx may 
be averaged over long-time periods (2–6 h) for comparison with 
subsequent CBF measurements (69).
A problem with PRx is the fact that the index is not related to 
a well-defined physiological mechanism or process. Accordingly, 
the data obtained should not be regarded as a definite measure 
of vascular resistance or autoregulation. For example, during 
the time period studied, CBF may change for many reasons not 
related to variations in MAP.
In several studies, PRx has been shown to correlate to clinical 
outcome in severe brain trauma (68, 70). It has been suggested 
that PRx could be used for targeting the optimal CPP (71, 72) 
but currently the evidence is not sufficient to make recommen-
dations for implementing this strategy (72). Furthermore, in 
patients with subarachnoid hemorrhage (SAH), the interpreta-
tion of PRx was ambiguous when compared to simultaneous 
measures of CBF, and it was concluded that PRx was not a 
reliable indicator of the status of autoregulation (69).
Summary: CBF and CBF Regulation
Presently, there is no technique available for quantitative, 
continuous monitoring of global or regional CBF during NCC. 
Three physiological mechanisms for regulation of CBF are of 
direct clinical importance: CO2-regulation, metabolic regulation, 
and pressure autoregulation. These basic mechanisms constitute 
important parts of non-surgical therapy of increased ICP.
CeReBRAL OXYGeNATiON
As normal cerebral function is completely dependent on oxidative 
energy metabolism bedside techniques offering possibilities of 
monitoring cerebral oxygenation are of obvious interest. Three of 
these techniques will be presented and discussed: monitoring 
of jugular venous oxygen saturation (SjvO2), brain tissue oxygen 
tension (PbtO2), and near-infrared spectroscopy (NIRS).
Jugular venous Saturation Monitoring
Monitoring of SjvO2 has been used widely in various clinical 
conditions: TBI, SAH, during neurosurgical procedures and 
NCC (73). Placement of the SjvO2 catheter is a relatively simple 
clinical routine procedure by a retrograde insertion of a jugular 
venous catheter. The tip of the catheter should be placed above 
the level of the C1/C2 disk to minimize the contamination from 
the facial vein (74). The choice of side is debated (75): the catheter 
can be placed on the side of the worst pathology, on the side where 
the internal jugular is most dominant, or bilaterally. Dominance 
may be determined by compression of each internal jugular vein 
separately and observation of the greater rise in ICP. Where there 
is no difference between the two sides, the right is commonly used 
as it is more likely to be the dominant side anatomically. SjvO2 
measurements can be obtained using intermittent blood samples 
or continuously with the use of fiberoptic catheters that use light 
wavelengths in the red/infrared spectrum to calculate saturation 
(74). Complications may occur during catheter insertion or due 
to prolonged duration in situ. Carotid artery puncture, hematoma 
formation, infection, thrombosis are possible complications but 
reported incidence is low (74).
Given stable arterial oxygen saturation and hemoglobin con-
centration SjvO2 is interpreted as reflecting the balance between 
cerebral oxygen delivery (supply) and the cerebral metabolic 
rate of oxygen (demand). Accordingly, an increase in SjvO2 may 
occur due to hyperemia (increased supply) or decreased CMRO2 
(decreased demand or inability to extract oxygen). A decrease 
in SjvO2 may occur due to hypoperfusion (decreased supply) 
or increased metabolic activity (increased demand). Therefore, 
SjvO2 may be considered as an indirect marker of CBF and cer-
ebral metabolism (73, 76).
The normal range of SjvO2 remains controversial. Generally, 
the lower range is considered to be 50–54% whereas 75% consti-
tute the upper range (74–78). SjvO2 desaturation <50% has been 
reported to be common following TBI associated with poorer 
outcome (74–78). Other clinical conditions that cause decreased 
SjvO2 include decreased systemic oxygen supply, hypoperfusion 
(e.g., hypotension, vasospasm, intracranial hypertension), and 
increased cerebral metabolism or oxygen extraction (e.g., hyper-
thermia, seizures) (73, 74, 79).
For obvious reasons, SjvO2 provides limited information in 
patients with focal cerebral ischemia. It has been estimated that 
an average of 170 ml of brain tissue was critically ischemic before 
SjvO2 levels dropped below 50% (80). Accordingly, the correla-
tion between SjvO2 and PbtO2 is often poor and high SjvO2 has 
been reported in patients with low PbtO2 and focal ischemia as 
well as in patients near to brain death (81, 82). Furthermore, it 
has been reported that SjvO2 monitoring was useful for only 43% 
of the time that the catheter was in situ, and only half of the time 
that PbtO2 monitoring was possible (83). Discrepancies found 
between SjvO2 measurements between left and right hemisphere 
raise concerns also as to the choice of catheter location (75).
Brain Tissue Oxygen Tension Monitoring
Monitoring of PbtO2 has been used extensively during NCC (TBI, 
SAH, cerebral infections) and during cerebral surgery (76, 84). 
The commercially available systems include Licox® (Integra 
Neurosciences, Plainsboro, NJ, USA) and Raumedic® (Raumedic 
AG, Helmbrechts, Germany). These probes come in different 
configurations, and the most advanced combines sensors for 
PbtO2, temperature, and ICP within a single catheter (Neurovent-
PTO), and the Licox® combines PbtO2 and temperature sensors. 
Different principles for measuring the PbtO2 are used in the 
two brands. The Raumedic® brand utilizes an optical method 
based on quenching of luminescence. Ruthenium is used as 
a luminophore and oxygen is the quencher. The Licox® is a 
polarographic electrochemical Clark-type cell electrode. This 
technique utilizes the electrochemical properties of noble metals 
to measure the surrounding oxygen partial pressure. The elec-
trode consists of a membrane covering a layer of electrolyte and 
two metallic electrodes: oxygen diffuses through the membrane 
and is electrochemically reduced at the cathode. The greater the 
oxygen partial pressure, the more oxygen diffuses through the 
membrane. The change in voltage between the reference elec-
trode and the measuring electrode is proportional to the amount 
of oxygen molecules reduced on the cathode. As the process is 
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temperature-dependent, a temperature probe is provided with 
the PbtO2 probe to correct for variations in tissue temperature 
may differ in patients. The two commercially available systems 
have been compared during in vitro and in vivo conditions (85). 
Generally, the Raumedic® sensors measured higher PbrO2 values 
(≈10%), but there was no significant difference regarding overall 
measurement or in vitro accuracy between the two probes.
PbtO2 varies with changes in arterial oxygen tension (PaO2) 
and CBF but exactly what PbtO2 measures remains to be 
defined (86–88). In the extensive clinical study by Rosenthal 
et al. (88), it was concluded that the product of CBF and the 
arteriovenous difference in oxygen tension had the strongest 
relationship with PbtO2. Several authors have, based mainly 
on clinical observations, suggested a threshold for PbtO2 below 
which hypoxic/ischemic cerebral damage occurs (83, 89–93). 
However, in an experimental study, it was concluded that the 
threshold values for PbtO2 under which energy metabolism 
fails was variable and most likely depending on the metabolic 
demands of the tissue (94). Accordingly, though PbtO2 may 
accurately describe the tension of oxygen in the tissue—which 
is determined by the blood flow, the blood oxygen tension, 
and oxygen diffusion through the tissue—but does not disclose 
whether this oxygen tension is sufficient for maintaining 
adequate metabolism or not. To answer the latter question, 
it is necessary to measure cerebral energy metabolism (see 
Microdialysis).
A relatively large number of clinical studies have suggested a 
relation between measured PbtO2 levels and mortality following 
TBI (83, 89–93, 95, 96). These studies have led to the hypothesis 
that PbtO2 monitoring could be used for targeting and improv-
ing intensive care in severe TBI (97–100). However, two recent 
publications found that PbtO2 guided therapy did not reduce 
mortality (101) and was associated with higher use of vasopres-
sors and higher cumulative fluid balance leading to higher ICP 
and pulmonary edema (102).
Near-infrared Spectroscopy
Near-infrared spectroscopy is based on the principle that near-
infrared light penetrates tissues well. About 40  years ago, the 
differential absorption of near-infrared light by oxyhemoglobin 
and deoxyhemoglobin was noted, and the technique was sug-
gested as method to measure circulation and oxygenation in 
the human brain non-invasively (103). As enzymes in the mito-
chondrial respiration chain also have differential characteristics 
of light absorption depending on their redox state (in particular 
cytochrome c oxidase), NIRS has also been suggested for estima-
tion of cellular metabolism (104, 105). Today, the technique of 
NIRS has a number of different medical applications (106).
As NIRS is a continuous, non-invasive monitor, it has been 
used extensively for cerebral monitoring. When the distance 
between incoming radiation and the reflected radiation reaching 
the optical sensor at the surface of the head is 30 mm, the returned 
radiation will pass through a depth of approximately 20 mm of 
tissue. Accordingly, information derived from this reflection is 
limited to the cerebral cortex. As the scattering coefficient of this 
optical path is unknown, the oxygenated/deoxygenated hemo-
globin level obtained is a relative rather than an absolute value. 
Normal range of cerebral regional oxygen saturation (rSO2) has 
been reported to be between 60 and 75%, but individual baseline 
variation has been reported to be as high as 10% (107, 108). The 
lack of standardization among NIRS devices contributes to the 
difficulty of establishing definitive threshold levels. A drawback 
of the technique is also that there may be a portion of the oxygen 
content that derives from the scalp, bone, and meninges.
A number of factors may affect the NIRS signals adversely. 
NIRS appears to be most limited when there is preexisting brain 
injury. In TBI, the accuracy is often reduced by tissue swelling 
and the presence of extravascular blood collections in the suba-
rachnoid, subdural, or intraparenchymal tissue compartments, 
the presence of subdural air after craniotomy, and a wet chamber 
between optical sensor and skin (109–111). Therefore, reports in 
TBI are conflicting. Some studies report that NIRS had a high 
failure rate and limited sensitivity in assessing rSO2 in severe TBI 
(110) while others have found the opposite (112, 113). Although 
the indication for NIRS appears to be limited within NCC, the 
technique is frequently used in other clinical situations when cer-
ebral oxygenation is of interest: extracorporeal circulation during 
open heart surgery, status post cardiac standstill. Accordingly, 
neuro-intensivists should be informed about the possibilities and 
limitations of the technique.
Comparison of SjvO2, PbtO2, and NiRS
The three techniques of SjvO2, PbtO2, and NIRS all permit bed-
side real-time, continuous data. The differences in information 
obtained is explained by the strengths and weaknesses of the three 
techniques and whether giving global (SjvO2) or regional (PbtO2, 
NIRS) information (83, 112, 113). Regional episodes of ischemia 
are accurately revealed by monitoring PbtO2 (81, 83) but, as it is 
a local technique, the accuracy is dependent on the position of 
the catheter in relation to focal lesions. SjvO2 and PbtO2 values 
correlate closely in response to changes in global parameters such 
as brain oxygenation and CPP (83, 114). SjvO2 gives information 
regarding global hemispheric oxygenation and may accordingly 
miss focal ischemia. These technical limitations should be con-
sidered when evaluating the estimation that a SjvO2 threshold 
of 50% approximately corresponds to PbtO2 of 8.5 mmHg (83). 
Correlation between NIRS and other measures of oxygenation 
is variable, and various results regarding such correlations have 
been reported (74, 78, 114). Of the three techniques, the impact 
of PbtO2 for prediction of clinical outcome has been evaluated in 
most detail in TBI studies. In a prospective study of 53 patients 
with severe TBI, the authors found that the use of both ICP and 
brain tissue PbtO2 monitors and therapy directed at brain tissue 
PO2 was associated with reduced patient death following severe 
TBI (115). Furthermore, in a recently published study, the authors 
found that reaching a critical PbtO2 threshold of ≤10  mmHg 
might be detrimental to cognitive outcomes following TBI (116).
Summary: Cerebral Oxygenation
All three brain oxygenation monitoring techniques exhibit spe-
cific advantages and limitations. PbtO2 monitoring is probably 
currently the technique most frequently used in NCC. Monitoring 
cerebral oxygenation provide valuable physiological informa-
tion that may help guide treatment. However, the interpretation 
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of these data rather than the monitoring itself will determine 
whether the patient will benefit from such technology.
TReATMeNTS OF eLevATeD iCP
Physiological Aspects on Surgical 
Treatments
Because the intracranial space is surrounded by the rigid skull, an 
increase in volume of one of the intracranial components must be 
at the expense of others:
 V V V V Vintracran blood brain CSF mass lesion    = + + +  (2)
This basic principle behind this hypothesis was formulated 
more than two centuries ago when a Scottish physician, 
Alexander Monro (1733–1817) applied some of the principles 
of physics to the intracranial contents. The hypothesis was 
supported by experiments by a Scottish surgeon George Kellie 
(1720–1779). In its original form, the hypothesis had shortcom-
ings that prompted modification by others. What finally came 
to be known as the Monro–Kellie doctrine, or hypothesis, is 
that the sum of volumes of brain, CSF, and intracranial blood 
is constant.
All surgical and non-surgical treatments of increased ICP aim 
at changing the volume of one or more of these components. The 
surgical treatments are directed toward three of these volumes: 
Vmass lesion, VCSF, and Vintracran. Following the initial resuscitation, 
early evacuation of significant focal mass lesions is the single 
most important treatment in patients with severe brain trauma 
(117, 118). CSF drainage, though it may be questioned from a 
theoretical point of view, can be used to reduce the amount of 
CSF in patients with remaining elevated ICP in spite of other 
measures. It is included in the recommendations by the US Brain 
Trauma Foundation (119). Craniectomy to increase the Vintracran 
is often advocated as a last resort for treatment of increased ICP 
(120, 121). All surgical treatments of increased ICP have one 
consequence in common: they all reduce Ptissue. In a pathophy-
siological situation with increased permeability of the BBB, a 
decrease in Ptissue leads to increased transcapillary water transport. 
The consequences are known to neurosurgeons: the gradual 
increase in ICP always observed after evacuation of a focal lesion; 
the collapse of the ventricles sometimes induced by ventricular 
drainage; the bulging of cerebral tissue through the craniectomy. 
Accordingly, the rapid change in volume obtained by surgery 
should always be combined with non-surgical treatments aimed 
at a slow and lasting reduction in brain water content (122–125).
Physiological Aspects on Non-Surgical 
Treatments
Transcapillary Absorption of Interstitial Water
From a physiological point of view, it is obvious that non-surgical 
treatments of increased ICP should primarily focus on transcapil-
lary reabsorption of interstitial water. The only way of inducing 
transcapillary fluid absorption is by controlling the transcapillary 
osmotic and hydrostatic differences (see Volume Regulation of 
the Brain). Mannitol, urea, glycerol, and hypertonic saline are 
used during intensive care to decrease brain volume by osmotic 
withdrawal of water (cf. Table 1). The effects of mannitol infu-
sion have been studied most widely. A rapid reduction of elevated 
ICP is usually obtained (126), but the effects of continuous or 
repeated infusions are not well documented. In experimental 
studies, multiple infusions of mannitol caused aggravation of 
cerebral edema resulting from interstitial accumulation (127). In 
addition to the osmotic effects, other possible benefits have been 
ascribed to mannitol, such as promoting CBF by decreasing blood 
viscosity (128) and scavenging of free radicals (129). However, 
no beneficial effect was obtained in a recent systematic review of 
mannitol therapy for increased ICP after acute ischemic stroke 
and cerebral parenchymal hemorrhage (130). A drawback of 
mannitol and urea is its shrinking effect of cells which promotes 
opening of the BBB.
As the intact BBB has a very low permeability for sodium 
chloride, intravenous infusion of hypertonic saline would be 
expected to decrease ICP. In experimental studies, a prompt 
and substantial decrease in cerebral water content has been 
documented after intravenous infusion of 7.5% saline solution 
(131), but the long-term effects are not well-documented. Several 
studies have shown beneficial effects of infusion of colloids 
in experimental brain trauma or stroke (132–136). A decrease 
in colloid oncotic pressure has been shown to aggravate brain 
edema after mild-to-moderate experimental brain trauma (137). 
In the “Lund Concept” presented later, preservation of the colloid 
osmotic pressure is obtained by albumin/plasma and red blood 
cell transfusions to normal albumin and hemoglobin values. In 
this protocol, albumin is the first choice because it is the main 
physiological colloidal substance of blood. Other colloids may be 
considered, but the use of human albumin is supported by the 
recent observation that albumin has a marked neuroprotective 
effect in experimental ischemic stroke (138).
The intracapillary hydrostatic pressure can be reduced by 
decreasing MAP, increasing precapillary vasoconstriction, or 
a combination of both. Both interventions reduce CBF, which 
may induce secondary injury—especially in vulnerable regions. 
This problem can be controlled at the bedside by monitoring 
regional cerebral energy metabolism. The physiological effects 
of reduced MAP are very different if the decrease results from 
reduced circulating blood volume or is caused by controlled 
antistress/antihypertensive treatment in a normovolemic 
patient (139). In the latter case, drugs (which affect peripheral 
circulation but do not cause intracranial vasodilatation) should 
be used. The combination of a β1-blocker (e.g., metoprolol) 
to reduce cardiac contractility and an α2-agonist (clonidine) 
to induce peripheral vasodilatation would be expected to be 
suitable, and CBF measurements in patients with severe head 
injury have documented that these drugs alone do not change 
cerebrovascular resistance (140).
BBB Permeability
In patients with peritumoral edema or interstitial edema sur-
rounding a focal brain infection, corticosteroids are used to 
decrease BBB permeability. However, in patients with severe brain 
trauma, ischemic stroke, intracerebral hemorrhage, or aneurys-
mal SAH, large clinical trials have not shown any beneficial effects 
of steroid treatment (141–144), and the American Association of 
FiGURe 6 | (A–F) Percentage changes in global cerebral blood flow (CBF), cerebral arterio-venous difference in oxygen (AVDO), intracranial pressure (ICP), and 
cerebro-vascular resistance (CVR) in patients with severe brain trauma. After the initial test with increased controlled ventilation (hyperventilation), the patients were 
assigned either to the group “Preserved CO2-reactivity” (A) or “Impaired CO2-reactivity” (B). After restoration of normoventilation, the patients were given either a 
bolus of thiopentone (C,D) (5–11 mg/kg intravenously) or a bolus of dihydroergotamine (e,F) (DHE; 4 mg/kg intravenously). *p < 0.05; **p < 0.01; ***p < 0.001 for 
significance of difference from control value. Data from Ref. (48, 156).
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Neurological Surgeons (AANS) concluded that the majority of 
available evidence indicates that steroids do not improve outcome 
or lower ICP in severe TBI (145). The reasons for the discrepancy 
between trauma and peritumoral edema are incompletely known, 
but it is reasonable to assume that the molecular mechanisms are 
different. The mechanisms leading to BBB breakdown and edema 
in trauma as wells in the peritumoral area have been studied 
extensively and were recently summarized in two comprehensive 
review articles (146, 147).
Experimental studies have indicated that low-dose continuous 
infusion of prostacyclin might improve cerebral microcircula-
tion and reduce capillary permeability (148, 149). Some clinical 
studies have indicated a possible beneficial effect of prostacyclin 
in severe TBI (150–153). To summarize, there is presently no 
therapy with documented effect for reduction of increased BBB 
permeability in patients with TBI or stroke. However, several 
novel promising strategies targeting the BBB have been presented 
in vitro and in vivo animal studies, though their relevance and 
signaling pathways in humans remain to be proven (147).
Intracranial Blood Volume
Since long it has been known that ICP and intracranial blood 
volume is decreased during hyperventilation (154, 155). The 
effect is obtained by constriction of precapillary resistance ves-
sels and always causes a reduction of CBF. Figure 6A shows the 
physiological effects of induced hyperventilation on global CBF, 
cerebral arterio-venous differences in oxygen content (AVDO), 
ICP, and cerebral vascular resistance (CVR) in patients with 
severe head injuries and preserved CO2 reactivity (data from 48). 
In patients with impaired CO2 reactivity (as defined by unchanged 
CBF), there was no change in CVR (Figure 6B) and the observed 
increase in AVDO and decrease in ICP were caused by regional 
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differences in blood flow regulation not revealed by the global 
CBF technique (48).
The cerebral physiological effects of indomethacin are similar 
to those of hyperventilation, and the effects are long-lasting (157). 
In animal experiments, however, the reduction of ICP caused 
by indomethacin was always associated with signs of cerebral 
ischemia (158), and, consequently, the clinical usefulness of indo-
methacin therapy may thus be questioned. Barbiturate therapy 
also reduces ICP by inducing precapillary vasoconstriction. The 
vasoconstrictor effect obtained by barbiturate is caused by the 
reduction in cerebral energy metabolism. The decrease in CBF is 
paralleled by a reduction in energy metabolism (cf. Figure 4) and, 
accordingly, the vasoconstriction should not increase the risk of 
cerebral ischemia (48). Figure 6C illustrates that the decrease in 
CBF and increase in CVR are not associated with the increase in 
AVDO (data from 48). In patients with impaired CO2 reactivity, 
the increase in CVR and the decrease in ICP were not obtained 
(Figure 6D). As these patients usually also have an impaired pres-
sure autoregulation, the minor decrease in CBF was interpreted 
to result from a decrease in MAP (48).
A cerebral vasoconstrictor ideal for treatment of increased 
ICP should have its main effect within the venous compartment 
and less effect on precapillary resistance (cf. Figure 2). In the 
peripheral circulation, dihydroergotamine (DHE) is known to 
preferentially constrict venous capacitance vessels (159) and 
DHE has been shown to decrease ICP in patients with severe 
head injuries (160). This effect was obtained, although CBF 
remained unaffected or increased and no increase in AVDO 
was obtained (156, 161). Figure  6E summarizes the cerebral 
physiological effects for patients with preserved CO2 reactivity 
(data from 156). Furthermore, as demonstrated in Figure  6F, 
DHE also decreased ICP in patients with impaired CO2 reac-
tivity (156), and in  vitro studies have shown that DHE has a 
more pronounced constrictor effect on isolated human cortical 
veins than arteries (162). The latter observation explains why a 
cerebral vasoconstrictor can cause a fall in ICP, although CBF 
remains unaffected or increases. As DHE is a non-specific recep-
tor stimulator, it may be associated with severe adverse effects 
and complications (163, 164). Sumatriptan is a more specific 
5-HT stimulator. It has been shown to decrease ICP in animal 
experiments (162), but thus far, it has not been used in clinical 
studies.
In summary, induced hyperventilation is effective for a short-
term decrease of ICP but is probably unsuitable for prolonged 
treatment. DHE decreases the ICP, and it does not reduce CBF 
or increase AVDO as its main effect is exerted on the venous 
compartment. However, DHE may cause severe side effects 
and complications. The ideal pharmacological vasoconstrictor 
remains to be defined but presently reduction of cerebral energy 
metabolism (usually obtained by infusion of a low-dose barbitu-
rate) is the first choice.
The “Lund Concept” Therapy of Increased ICP
The “Lund concept” was originally developed to treat patients with 
severe brain trauma, impaired CO2 reactivity, and a dangerous 
increase in ICP (122). In these patients, conventional therapies 
of increased ICP appeared to be ineffective (40, 48). The protocol 
has later been used in all patients with severe traumatic brain 
lesions as well as in patients with other cerebral disorders with 
increased ICP. For obvious reasons, the “Lund Concept” is not 
used in conditions with compromised arterial blood flow (e.g., 
arterial vasospasm after SAH).
In patients with head injury, the therapy begins after initial 
resuscitation and surgical evacuation of focal mass lesions. The 
patients are treated with controlled normoventilation (without 
muscle relaxation) under continuous monitoring of MAP and 
ICP. In 1995, the technique of intracerebral microdialysis and 
bedside biochemical analysis of cerebral energy metabolism 
was introduced to document that the therapy did not cause a 
dangerous decrease in CPP. The protocol followed in the “Lund 
Concept” is based on the physiological considerations mentioned 
earlier and can be summarized as follows.
Reduction of Stress Response and Cerebral Energy 
Metabolism
Stress response is initially reduced by liberal use of sedatives 
(benzodiazepines). A further reduction of the stress response 
and catecholamine release is obtained by a continuous infusion 
of low-dose thiopental (0.5–3  mg/kg/h) and fentanyl (2–5 μg/
kg/h). The dose of thiopental is kept low to avoid cardiac inhi-
bition, pulmonary complications, and other side effects (50). 
A protective effect of β1-blockade after head injury, through 
reduction of sympathetic nervous system effects on the heart 
and lungs have been suggested. Reports of the beneficial effect 
of β-blockade in head injury with regard to survival have been 
published (165–168).
Reduction of Capillary Hydrostatic Pressure
Mean arterial pressure is reduced to the physiological level 
for the age of the individual patient with a combination of the 
β1-antagonist metoprolol (0.2–0.3  mg/kg/day, intravenously or 
as a low continuous intravenous infusion) and the α2-agonist 
clonidine (0.4–0.8 μg/kg, 4–6 times/day, or a low dose of con-
tinuous, intravenous infusion) (125, 140). The antihypertensive 
treatment is initiated after evacuation of focal mass lesions when 
the patients are clearly normovolemic (as obtained by red blood 
cell and albumin/plasma transfusions to normal albumin and 
hemoglobin values and to a normal central venous pressure). A 
CPP of 60–70 mmHg is considered optimal; however, if necessary, 
a transient decrease in CPP (to 50 mmHg in adults and 40 mmHg 
for children) is accepted to control ICP (122).
Maintenance of Colloid Osmotic Pressure and Control of 
Fluid Balance
Red blood cell transfusions and albumin are administered 
to achieve normal values (Hemoglobin: 125–140  g/l, Serum-
albumin: approximately 40 g/l) to ensure normovolemia and to 
optimize oxygen supply. The albumin/plasma/blood transfusions 
also serve the purpose of obtaining a normal colloid osmotic 
pressure, favoring transcapillary absorption. A balanced or mod-
erately negative fluid balance is a part of the treatment protocol 
and is achieved by diuretics (furosemide) and albumin infusion. 
All patients are given a low-calorie enteral nutrition (max energy 
supply: 15–20  kcal/kg/day). These physiological principles 
FiGURe 7 | Schematic illustration of the theoretical principles behind the 
“Vasoconstrictor Cascade” according to Rosner et al. (172).
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followed during NCC are supported by experimental studies 
(123, 125, 169–171).
Reduction of CBV
Intracranial blood volume may be reduced both on the arte-
rial side with thiopental (48) and DHE (159–161) and on the 
venous side with DHE (156, 161). However, due to the serious 
complications related to DHE therapy (163, 164), this treatment 
is rarely used.
The “Vasoconstrictor Cascade” Therapy  
of Increased ICP
The “Lund Concept,” advocating a reduction in CPP, was first 
presented in 1994 (125). In 1995, a contradictory protocol based 
on physiological considerations and advocating a pharmacologi-
cally induced increase in CPP as therapy for increase in ICP was 
published (172). The therapeutic principle was based on the 
so-called “Vasoconstrictor Cascade.”
The theory was based on the hypothesis that in patients with a 
functioning pressure autoregulation an increase in MAP would, 
due to the induced vasoconstriction, cause a decrease in CBV 
and hence also a decrease in ICP (Figure  7). In patients with 
supposed impaired pressure autoregulation, it was assumed that 
the autoregulation curve was often shifted to a higher MAP level. 
By this mechanism, the authors postulated that marked increase 
in MAP from a vigorous use of vasopressors would result in a 
decrease in CBV and ICP: “Cerebral perfusion pressure manage-
ment can serve as the primary goal in the treatment of traumatic 
intracranial hypertension with substantially improved mortality 
and morbidity following TBI. The minimum level of CPP in this 
instance is greater than 70 mm Hg and frequently higher, defined 
by individual circumstances that may occasionally require a level 
of 100 mm Hg or more, but average 85 mm Hg. Systemic hyper-
tension and iatrogenic maintenance of CPP do not potentiate or 
worsen intracranial hypertension” (172).
Does the “Vasoconstrictor Cascade” comply with accepted 
physiological principles? By definition pressure autoregulation 
implies that CBF remains constant. CBF is controlled by the 
constriction/dilatation of the precapillary resistance vessels 
(Figure 2). As stated above, all surgical and non-surgical treat-
ments of increased ICP act by changing the volume of one or more 
of these components. Assuming that the total intracranial volume 
is 1,500  ml (Vblood ≈75  ml) the distribution of the volumes of 
blood are approximately Vvenous 50–55 ml, Varterial 10–20 ml, Vcapillaries 
5–10 ml. Probably, the vessels responsible for autoregulation are 
small pial arteries with diameters between 200 and 400 µm (cf. 
above CBF, autoregulation). A decrease in diameter of these small 
vessels would accordingly cause a minor decrease in intracranial 
blood volume. However, by definition pressure autoregulation 
implies that CBF remains constant and, as discussed above, the 
decrease in CBV and ICP caused by constriction of precapillary 
resistance vessels occur at the expense of a reduction of CBF. 
Furthermore, according to the Poiseuille–Hagen equation, the 
flow through a vessel is proportionate to the radius to the fourth 
(R4), while the volume is proportionate to R2. Accordingly, it 
seems unlikely that preserved capacity for autoregulation and 
pharmacological increase in MAP could be useful for treatment 
of increased ICP. When tested in acutely head injured patients, it 
was documented that vasopressor therapy resulted in a marked 
increase in ICP in the group with severe brain trauma (126).
Summary: Treatments of elevated iCP
All treatments of elevated ICP act by reducing one or more of the 
intracranial volumes (or increasing the total available volume through 
craniectomy). Non-surgical treatments act by decreasing brain and/
or blood volume. The “Lund concept” is based on the physiological 
principles for regulation of these volumes. Many of these aspects are 
now included in protocols for treatment of increased CBF. However, 
it is still motivated to mention that the common belief that ICP may 
be decreased by an induced increase in MAP (“Vasoconstrictor 
cascade”) is not supported by known physiological principles.
CeReBRAL eNeRGY MeTABOLiSM
The human brain constitutes only about 2% of the body weight 
but approximately 20% of the total body energy is consumed 
by the brain. To cover this very high energy demand, CBF 
constitutes 15% of cardiac output. The majority of the energy 
is used for active transport of various compounds against their 
concentration gradients, and it is estimated that less than 20% of 
the energy utilized by the brain is used for biosynthesis of cellular 
components. Due to the fact that glucose is the only substrate that 
is transported across the BBB at sufficient speed, glucose is under 
normal circumstances the sole substrate utilized by the brain. In 
the cytoplasm of the cells, glucose is converted to pyruvate (and 
lactate). The main part of the energy is obtained after pyruvate 
has entered into the citrate cycle in the mitochondria, ultimately 
being completely degraded to carbon dioxide and water. Global 
cerebral energy metabolism can be evaluated by measuring CBF 
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and arterial venous difference in oxygen content. These basic 
physiological and biochemical principles of cerebral energy 
metabolism have been known for decades and were described 
in a textbook in 1978 (29). However, as pathophysiological 
processes are often focal global, techniques for the evaluation 
of metabolism may give information of limited importance 
during NCC. Furthermore, it would be of clinical importance to 
monitor cerebral energy metabolism and indicators of cellular 
damage bedside. Intracerebral microdialysis is presently the only 
technique that offers this possibility.
Microdialysis
The microdialysis technique was developed more than 30 years 
ago for monitoring chemical events in the animal brain (173, 174) 
and has become an accepted scientific standard technique. Alto-
gether, there have been well above 16,000 published studies 
utilizing microdialysis. In the late 1980s, the possibilities for 
monitoring the human brain were first explored (175–177), and 
microdialysis has since then been used for biochemical monitoring 
of most human tissues. In 1995, CMA Microdialysis (Stockholm, 
Sweden; present manufacturer M Dialysis, Stockholm, Sweden) 
introduced a sterile microdialysis catheter, a simple microdialysis 
pump and a bedside biochemical analyzer. The instrumentation 
was originally intended for subcutaneous and intramuscular use. 
With a slight modification of the microdialysis catheter, it has 
been used intracerebrally as an integrated part of routine multi-
modality monitoring since 1996.
The Microdialysis Technique
The original idea of microdialysis was to mimic the function of 
a blood capillary by inserting a thin dialysis tube in the tissue 
to analyze the chemical composition of the interstitial fluid. 
However, though the microdialysis catheter is thin (0.6 mm), it 
is much wider than a capillary and far bigger than the estimated 
intercellular distance (about 0.0001 mm). The wall of the catheter 
allows free diffusion of water and solutes between the surround-
ing interstitial fluid and the perfused solution (perfusate). The 
concentration gradients between the interstitial fluid and the 
perfusate constitute the driving force for diffusion. The molecular 
weight of the molecules being sampled is limited by the pore size 
of the dialysis membrane (cutoff). The perfusate flows along the 
dialysis membrane slowly and at a constant speed, and the sample 
(dialyzate) is collected in microvials and analyzed biochemically 
bedside by utilizing enzymatic, colorimetric techniques.
The achieved concentration of the analytes in the dialyzate 
depends on the degree of equilibration between the interstitial 
fluid and the perfusate. This relation is termed (relative) recovery 
and is defined as the dialyzate/interstitial concentration ratio 
expressed as percentage: Recovery = Concdialyzate/Conctissue.
Accordingly, the microdialysis technique does usually not give 
the absolute concentration of the studied biochemical variables. 
When clinical microdialysis is performed as a routine technique, 
this limitation is without significance. However, some of the fac-
tors determining the recovery are important to recognize.
The three most important factors affecting recovery in vivo are 
the area of the semi-permeable membrane (length of microdialy-
sis membrane), the perfusion flow rate, and the diffusion in the 
surrounding interstitial fluid. The recovery increases in propor-
tion to the length of the dialysis membrane area. The 70 Brain 
MD Catheter routinely used in the brain has a membrane length 
of 10 mm. The diameter of the probe is about 0.6 mm, and the 
standard cutoff of the dialysis membrane (during clinical routine) 
is 20  kDa. For special scientific purpose (monitoring of large 
molecules, e.g., cytokines), microdialysis catheters with 100 kDa 
cutoff are commercially available (178). The standard perfusion 
flow rate used during clinical routine is 0.3 µl/min, which allows 
sampling for bedside analysis every 30  min. Due to the slow 
perfusion rate and the large dialysis membranes, recovery is high: 
the in vivo recovery for the intracerebral 70 Brain MD Catheter is 
approximately 70% for the biochemical variables used routinely 
(179). If the perfusion rate is increased to permit more frequent 
sampling, recovery decreases to about 30% at 1 µl/min (179).
The diffusion rate in the surrounding interstitial space is of 
importance and varies with the molecular weight of the stud-
ied analytes and size and tortuousity of the interstitium. The 
recovery may thus vary between tissues and changes with the 
pathophysiological conditions. The problem is unimportant for 
clinical routine but is very relevant, for example when microdi-
alysis is used for quantitative pharmacokinetic studies (180, 181). 
The importance of the diffusion limitation of the surrounding 
interstitial space also explains why it is useless to perform in vitro 
calibration to compensate for the recovery in vivo.
Biochemical Variables Monitored during  
Clinical Routine
The biochemical variables used for routine monitoring during 
clinical conditions were chosen to cover important aspects of cer-
ebral energy metabolism and to give indications of degradation 
of cellular membranes. Figure 8 shows these variables and their 
reference levels as obtained in normal human brain (182). Under 
normal conditions, glucose is the sole substrate for cerebral energy 
metabolism. In the cytosol, it is degraded to pyruvate (glycolysis) 
with a net yield of two ATP for each molecule of glucose. Due to 
the redox conditions, part of the pyruvate is converted to lactate. 
The lactate/pyruvate (LP) ratio reflects cytoplasmatic redoxstate, 
which can be expressed in terms of the lactate dehydrogenase 
equilibrium:
 
NADH  H
NAD
Lactate
Pyruvate+ LDH
[ ] [ ]
[ ] =
[ ]
×
+
[ ]
K
 
(3)
Thus, the LP ratio gives information regarding the efficacy of 
cerebral oxidative energy metabolism. The major part of pyruvate 
enters the citric acid cycle in the mitochondria and is completely 
degraded to CO2 and H2O with a net yield of another 36 ATP. The 
chemical relation between the citric acid cycle and the excitatory 
transmitter glutamate is shown in Figure 8. However, the gluta-
mate level obtained by microdialysis does not exclusively reflect 
liberation of the transmitter. As interstitial glutamate is normally 
rapidly taken up by the astrocytes against a concentration gradient 
(183), an increase in interstitial glutamate is often an indicator of 
jeopardized energy metabolism and release from leaky cells (184).
Since the brain does not contain any triglycerides (TG), a 
high level of intracerebral glycerol is considered to be a reliable 
FiGURe 8 | Schematic diagram of cerebral intermediary metabolism, with a focus on the glycolytic chain and its relation to glycerol and glycerophospholipids and to 
the citric acid cycle (Krebs cycle). F-1,6-DP: fructose-1,6-diposphate; DHAP, dihydroxyacetone-phosphate; GA-3P, glyceraldehyde-3-phosphate; G-3-P, glycerol-3-
phosphate; FFA, free fatty acids; α-KG, α-ketoglutarate. Underlined metabolites are measured at the bedside with enzymatic techniques. References levels of the 
various metabolites for normal human brain obtained from Ref. (182).
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indicator of degradation of the glyceropospholipids of cellular 
membranes and cell damage (185, 186). In other tissues, and in 
particular in fat tissue, glycerol is mainly obtained from degra-
dation of TG. Lipolysis is under sympathetic control through 
catecholamine receptors on the adipocytes, which are stimulated 
by circulating catecholamines as well as by local noradrenergic 
nerve endings. The glycerol level in subcutaneous fat tissue may 
be used as an indicator of physical as well as mental stress (187).
During clinical routine, the biochemical variables may be ana-
lyzed bedside (ISCUSflex, MDialysis, Stockholm, Sweden). An 
analytical validation of the enzymatic techniques used for analy-
sis of glucose, lactate, and pyruvate has recently been presented 
(188). For critical threshold, intra- and interassay coefficients of 
variation (CV) were, respectively, 3.1 and 4.5% for glucose, 3.5 and 
4% for lactate, and 3.3 and 4.3% for pyruvate and inter-assay CV 
for LP ratio was 5.9%. The data prove that these routine analyses 
have the accuracy and precision required for clinical application 
in neurointensive care but the CV must be considered when these 
analytical techniques are used for scientific purpose (189).
Intracerebral Microdialysis in NCC
Though microdialysis has been used in most human tissues, 
the majority of clinical studies utilizing microdialysis have been 
performed in the brain. The biochemical variables routinely ana-
lyzed bedside were chosen to cover important aspects of cerebral 
energy metabolism (glucose, pyruvate, and lactate), to indicate 
excessive interstitial levels of excitatory transmitter substance 
(glutamate) and to give indications of degradation of cellular 
membranes (glycerol) (Figure 8). Most basic principles regarding 
cerebral energy have been known since decades (29) and similar 
patterns of changes have been described when utilizing intracer-
ebral microdialysis. Figure 9 shows changes in the intracerebral 
levels of glucose, lactate, and pyruvate after induction of cerebral 
ischemia, and in Figure 10, the simultaneous changes in LP ratio 
in the levels of glutamate and glycerol are shown (190). In this 
study, transient brain ischemia was induced in fetal lambs in utero 
by occlusion of the umbilical cord followed by resuscitation after 
cardiac standstill. The microdialysis technique was identical to 
that used during clinical conditions, but the perfusion rate was 
increased (1.0  µl/min) to allow frequent sampling. Induction 
of ischemia caused an almost instantaneous increase in the LP 
ratio shortly afterward followed by an increase of the glutamate 
level. Glucose, pyruvate, and glutamate rapidly recovered after 
resuscitation, but the levels of lactate and glycerol continued to 
be elevated and the LP ratio remained slightly above the pre-
ischemic level.
These data are of importance for the interpretation of our 
clinical findings. The LP ratio, reflecting the redox state of the 
cytoplasm, will increase immediately when delivery of oxygen 
is insufficient and will rapidly return close to normal upon re-
oxygenation. The lactate level rapidly increases during ischemia 
but remains elevated when circulation is restituted. Glycerol, the 
indicator of degradation of cellular membranes, increases rela-
tively slowly during energy failure and remains elevated for some 
FiGURe 10 | Changes in intracerebral biochemistry during transient global cerebral ischemia. Levels of lactate/pyruvate (LP) ratio, glutamate, and glycerol 
(mean ± SD). Data from Ref. (190).
FiGURe 9 | Changes in intracerebral biochemistry during transient global cerebral ischemia. Levels of glucose, lactate, and pyruvate (mean ± SD).  
Data from Ref. (190).
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time when energy metabolism is normalized. The interstitial 
glucose level, finally, reflects the balance between delivery from 
the blood capillaries and the cellular uptake.
It is important to realize that the microdialysis technique 
gives biochemical information only concerning a small volume 
surrounding the catheter since regional differences in blood 
FiGURe 11 | Bar graphs demonstrating mean (±SD) lactate/pyruvate (LP) ratio in the better (white bar) and worse (gray bar) microdialysis catheter positions in 
relation to four ranges of cerebral perfusion pressure (CPP) in patients with severe traumatic brain lesions. Interrupted lines indicate the range (mean ± SD)  
in healthy brains in humans during wakefulness. Data from Ref. (182, 194), respectively.
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flow and energy metabolism are considerable in most patho-
physiological conditions. The fact that microdialysis is a regional 
technique may thus be regarded as an advantage provided that 
the positioning of the catheters can be visualized in relation to 
the focal injuries. Furthermore, one must be aware of the dynam-
ics of the tissue condition which may considerable change with 
time (191). Thus, if the tissue targeted at catheter insertion was 
the “worst site,” it may be less so after a while due to the evolution 
of tissue damage.
It has been possible to identify the metabolic pattern in vari-
ous parts of the injured brain by inserting multiple intracerebral 
microdialysis catheters in patients with severe traumatic brain 
lesions. The studies have shown that “biochemical penumbra 
zones” surround focal brain lesions and that most adverse second-
ary events primarily affect these sensitive zones (192, 193). Thus, 
intracerebral microdialysis with bedside biochemical analysis 
may be used to detect and treat focal adverse events before they 
have caused cellular degradation or clinical deterioration that 
may be detected by conventional monitoring.
Intracerebral microdialysis has been used to determine the 
lower acceptable limit for CPP in the individual patient (194, 
195) (Figure 11). As discussed previously, this level is of par-
ticular importance in patients with increased ICP partly due to 
brain edema. In these patients, a high CPP may increase the 
intracapillary hydrostatic pressure and cause a net transport 
of water into the brain tissue interstitium which will further 
increase ICP (see Volume Regulation of the Brain).
Bedside Diagnosis of Cerebral ischemia 
and Mitochondrial Dysfunction
During NCC, microdialysis has primarily been focused on iden-
tifying episodes of secondary clinical ischemia. However, several 
studies have documented that during NCC prolonged distur-
bance of cerebral energy metabolism and increase of LP ratio 
were often not due to ischemia as cerebral oxygenation remained 
unaffected (196). Already in the 1970s, animal experiments had 
shown that transient cerebral ischemia often lead to a prolonged 
period of mitochondrial dysfunction (197, 198).
The biochemical pattern obtained during mitochondrial dys-
function has been described recently (199, 200). The results are 
shown schematically in Figure 12 and compared with the cor-
responding metabolic pattern in cerebral ischemia. In cerebral 
ischemia, the interruption of blood flow and decrease in PbtO2 
causes a very rapid increase in LP ratio (Figures 9 and 12A). As 
the cerebral delivery of substrate for energy metabolism (glu-
cose) is also interrupted, pyruvate decreases to a very low level 
and, as a result, the LP ratio increases to extremely high levels. 
In mitochondrial dysfunction, PbtO2 is unchanged but, due to 
impaired mitochondrial function, oxidative metabolism is insuf-
ficient to meet the energy demands. The increase in glycolytic 
rate causes a massive production of lactate and increase in the 
LP ratio although tissue pyruvate remains at a normal level or 
increases slightly (Figure  12B). Under clinical conditions, an 
increase in LP ratio may be caused by a variety of mechanisms 
(201). Drugs that are effective in mitochondrial dysfunction are 
FiGURe 12 | Schematic illustration of cerebral tissue oxygenation (PbtO2) and 
changes in the levels of lactate (La), pyruvate (Py), and the lactate/pyruvate 
(LP) ratio in experimental cerebral ischemia (A) and mitochondrial dysfunction 
(B). Data from Ref. (200).
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presently under investigation. One example is cyclosporine A, 
which is thought to decrease mitochondrial damage by blocking 
opening of the mitochondrial permeability transition pore (202). 
The protective effect of cyclosporine in cerebral ischemia was 
in 1995 described in experimental studies (203). However, its 
clinical usefulness has not yet been documented. Irrespective 
of the mechanisms underlying mitochondrial dysfunction, a 
beneficial therapeutic intervention would probably be reflected 
in normalization of the biochemical variables analyzed and 
displayed at the bedside.
Lactate Supplementation for Treatment  
of TBi Patients
Based on association with the so-called astrocyte-to-neuron lac-
tate (ANL) shuttling hypothesis, a number of publications have 
suggested the use of lactate as supplemental brain fuel after TBI. 
The ANL shuttle model was based on an observed glutamate-
evoked release of lactate in cultured astrocytes indicating that 
glycolysis provides the ATP needed for astrocytic uptake of neu-
rotransmitter glutamate and its conversion to glutamine and the 
assumption that the released lactate is oxidized by nearby neurons 
(204). However, ANL shuttling has never been quantified and 
validated as being metabolically significant in living brain, the 
cellular source(s) of lactate in brain have not been identified, and 
there are many independent lines of strong evidence against the 
lactate shuttle model. Accordingly, lactate shuttling and utiliza-
tion has remained a controversial issue (205–212). In vitro studies 
have shown that lactate can maintain ATP levels but not sustain 
neuronal signaling (213–217). These observations underscore the 
critical roles of glucose metabolism upstream of pyruvate/lactate 
for neuronal function.
It is well documented and uncontroversial that lactate may 
serve as a supplemental brain fuel when its blood level is elevated 
and exceeds the intracerebral level for example during exercise 
or lactate infusion (218–220). However, it is important to note 
that the metabolic efficacy of lactate supplementation depends 
on functional integrity of mitochondria (211). This fact has some-
times been overlooked which may lead to unfortunate clinical 
decisions (221, 222). A prior assessment of oxidative capability in 
each patient would be required if the metabolic benefits of lactate 
were to be evaluated.
Furthermore, it is important to remember that lactate trans-
port across the BBB is an example of facilitated diffusion. The 
transport does not directly require chemical energy from ATP 
hydrolysis but the lactate molecules move down their concentra-
tion gradient. Accordingly, net transport of lactate into the brain 
requires that blood lactate level is higher than its intracerebral 
concentration. Thus, the recent report that transport of lactate 
into the brain may occur against a concentration gradient in 
brain trauma patients is erroneous (223). The observation is 
fully explained by the imprecision of the biochemical analytical 
biochemical techniques used (189).
As discussed previously, the BBB has a very low permeability 
for sodium (cf. Table  1). Accordingly, infusion of hypertonic 
sodium lactate is usually effective in reducing a dangerous increase 
in ICP (224, 225). If, in a patient with compromised CBF due 
to high ICP, hyperosmolar therapy decreases ICP, improvement 
of cerebral energy metabolism would be expected and does not 
indicate a specific beneficial metabolic effect of lactate infusion. 
For example, in a series of patients with cerebral hemorrhage 
and ICP > 20 mmHg, infusion of mannitol (1 g/kg) resulted in a 
significant decrease in ICP and cerebral LP ratio, increased CPP, 
and unchanged PbtO2 and concentration of cerebral glucose (226). 
In a situation of compromised cerebral energy metabolism and 
an increase of LP ratio, lactate flooding is associated with con-
siderable risk. For example, it may inhibit glycolytic and pentose 
shunt fluxes in neurons and astrocytes and impair glycogenolysis 
in astrocytes (212).
Bedside evaluation of Cerebral energy 
State—Future Possibilities
As the microdialysis probe reflects the biochemistry from a very 
narrow zone surrounding the dialysis membrane, appropriate 
positioning of the catheter in relation to focal lesions is necessary 
for a correct interpretation of the data obtained (193). During 
NCC, information regarding global cerebral energy state in 
addition to the regional information obtained from conventional 
intracerebral microdialysis would be valuable. Such information 
would also be of importance during critical care of other severe 
conditions when cerebral energy metabolism may be jeopardized 
without focal lesions (e.g., open-heart surgery, resuscitation after 
cardiac standstill, hemorrhagic or septic shock, toxic states). 
However, in these conditions, it is for various reasons difficult 
or impossible to insert intracerebral catheters. An alternative 
technique that avoids the penetration of cerebral tissue and still 
gives continuous bedside information regarding global cerebral 
energy state would be of apparent interest.
In a recent experimental study of induced hemorrhagic 
shock, the LP ratio in the draining cerebral vein (superior sagittal 
sinus) was compared to the LP ratio obtained from simultaneous 
intracerebral and intra-arterial microdialysis (227). In patients 
undergoing open heart surgery with cardio-pulmonary by-pass 
(CPB), a similar technique has been presented. The LP ratio 
obtained from microdialysis of the internal jugular vein increased 
significantly during CPB, indicating compromised cerebral oxi-
dative metabolism, while conventional monitoring by NIRS did 
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not show a corresponding decrease in cerebral oxygenation (228). 
Future studies will show whether the LP ratio obtained from 
draining cerebral venous blood will be informative enough to be 
used as a method to evaluate cerebral global energy state bedside.
Presently, the microdialysis technique used in clinical routine 
does not permit online monitoring. Today, the technique is 
laborious since it is necessary for the NCC personnel to transfer 
microvials at regular time intervals from the microdialysis cath-
eter to the bedside analyzer. Techniques utilizing biosensors for 
true online monitoring are under development (229). By utilizing 
these techniques, it will probably in the near future be possible 
to monitor glucose, lactate, and pyruvate online bedside during 
NCC. If the LP ratio obtained from microdialysis of cerebral 
venous blood gives useful information regarding global cerebral 
redox state, we might in the near future have the possibility to 
monitor global cerebral energy state online. The technique might 
be used not exclusively during NCC but also during general 
intensive care where insertion of an intracerebral catheter is 
contraindicated or impossible.
Summary: Cerebral energy Metabolism
Since decades, the biochemistry of cerebral energy metabolism 
has been studied and documented in animal experiments. The 
microdialysis technique permits bedside monitoring of the most 
important biochemical variables during NCC. For a correct 
interpretation of the data, it is important to be aware of the pre-
requisites and limitations of the micordialysis technique and the 
biochemical analyses. The information obtained gives informa-
tion regarding cerebral energy state and can be used to separate 
cerebral ischemia from mitochondrial dysfunction. However, 
the biochemical data obtained by intracerebral microdialysis are 
representative of a very small volume of tissue. Accordingly, a 
correlation to clinical outcome would be expected only when 
the volume studied is representative of a relatively large part of 
the brain. Future routine bedside monitoring of cerebral energy 
metabolism will probably depend on whether techniques permit-
ting true online biochemical analysis by sensors are presented.
CONCLUDiNG ReMARKS
Neurocritical care is especially focused on problems related to 
ICP, CBF, and cerebral energy metabolism. Specific monitoring 
techniques have been introduced to give information regarding 
variables within these areas. To be of real importance for NCC, 
the techniques must give data that are obtained frequently/con-
tinuously, presented bedside and included in the clinical decision 
making. The information presented may be representative of a 
large part of the brain (global technique) or a very small volume 
surrounding the probe (focal technique). Both techniques have 
specific advantages and disadvantages. Many clinical studies have 
been devoted to examine the relation between the data obtained 
and clinical outcome. These efforts are not always motivated 
and may be questioned for several reasons. Most importantly, 
though physiological and biochemical data obtained by a global 
technique might be related to outcome, it is not justified to use 
data from a focal technique in this way unless it is known that 
these data are representative of a large part of the brain. Other 
clinical studies have examined possible correlations between 
the different physiological and biochemical techniques. Such 
correlations may be justified provided it is known that there is a 
physiological or biochemical relation between the variables. We 
will here briefly summarize our opinions regarding some of the 
techniques discussed previously.
Global Physiological Techniques
Intracranial pressure is a keystone within NCC and CPP is 
calculated from ICP and the simultaneously monitored MAP. 
To be of clinical importance, ICP must be measured accurately 
and displayed continuously at the bedside. Presently, this may be 
achieved in two ways: from an intra-ventricular catheter or from 
a pressure-sensitive sensor placed in the brain.
The index named PRx is not related to a well-defined physi-
ological mechanism or process, and the data obtained should 
not be regarded as a definite measure of vascular resistance or 
autoregulation. Several clinical studies have tried to correlate 
PRx with PbtO2 as well as with biochemical data obtained from 
microdialysis. As the mechanism behind PRx is not defined it is 
unclear why this global variable should be expected to correlate 
with any of these two focal techniques.
Under physiologically stable conditions, SjvO2 is interpreted 
as reflecting the balance between cerebral oxygen delivery and 
the cerebral metabolic rate of oxygen. However, the normal range 
of SjvO2 remains controversial, it provides limited information in 
patients with focal lesion, and technical monitoring problems are 
common. For obvious reasons, the correlation between SjvO2 and 
PbtO2 is often poor.
Focal Physiological Technique
PbtO2 gives online information regarding tissue oxygen tension 
which is determined by the blood flow, the blood oxygen tension, 
and oxygen diffusion through the tissue. However, it does not 
disclose whether this oxygen tension is sufficient for maintaining 
adequate metabolism, and it has not been possible to define a 
threshold for PbtO2 below which hypoxic/ischemic cerebral 
damage occurs. As PbtO2 monitoring is a focal technique, a cor-
relation to clinical outcome would be expected only when the 
data obtained reflects the situation in a relatively large part of 
the brain. The prerequisites for expecting a correlation between 
PbtO2 and LP ratio is discussed in the following paragraph.
Focal Biochemical Technique
Presently, intracerebral biochemistry can only be evaluated bed-
side by utilizing microdialysis. During NCC routine, biochemical 
analyses can be used to give bedside information on cerebral 
energy status and signs of acute cellular degradation. In clinical 
praxis, it is important to use the technique in a standardized 
fashion which allows comparison between the data obtained and 
the levels observed in normal human brain. Routine biochemi-
cal analysis allows a clinically important separation of cerebral 
ischemia and mitochondrial dysfunction. The biochemical infor-
mation obtained is representative of a very small tissue volume 
and a correlation to clinical outcome would be expected only 
when the conditions in this volume is representative of large part 
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of the brain. As the LP ratio reflects cytoplasmatic redox state, a 
correlation to PbtO2 would be expected during cerebral ischemia 
but not during mitochondrial dysfunction.
Global Biochemical Techniques
Presently, there is no technique available for evaluation of global 
cerebral energy state during NCC. Intraventricular insertion of 
the microdialysis catheter might be used in combination with 
conventional biochemical analysis, but the clinical benefits of 
this procedure have so far not been explored. Whether the LP 
ratio obtained from the draining cerebral venous blood might be 
informative is presently studied under experimental and clinical 
conditions. If the technique can be shown to give information 
regarding “global cerebral redox state,” it might be used to evalu-
ate cerebral energy state also in clinical situations where insertion 
of an intracerebral catheter is risky or impossible.
General Considerations for the Future
Future progress within NCC will necessitate a close collaboration 
between clinicians, experimental laboratories and companies 
developing new products for bedside monitoring and analysis. 
All physiological and biochemical interpretation should be based 
on solid data obtained in controlled experimental studies. It is 
important to realize that new biochemical principles will not be 
discovered under clinical conditions by utilizing routine bedside 
analytical techniques. For the intensivist working within NCC, 
it is already today a demanding task to interpret the interrelated 
and complex physiological and biochemical variables displayed 
bedside. In the future, this complexity will probably increase. To 
meet this development, the future intensivist will need deeper 
theoretical knowledge and, ideally, experiences from experi-
mental studies within these specific areas of importance. Finally, 
the clinicians utilizing advanced monitoring techniques must 
understand the underlying principles and the limits and pitfalls 
associated with each specific method.
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